{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:14:24Z","timestamp":1779891264726,"version":"3.53.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00066-026-02520-5","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:15:08Z","timestamp":1774890908000},"page":"683-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metaanalyse zur stereotaktischen Bestrahlung von Oligometastasen beim Prostatakarzinom (WOLVERINE-Metaanalyse)","WOLVERINE, a\u00a0meta-analysis on stereotactic radiotherapy of oligometastases in prostate cancer"],"prefix":"10.1007","volume":"202","author":[{"given":"J\u00fcrgen","family":"Dunst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2520_CR1","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini\u00a0G, Allegra\u00a0AG, Detti\u00a0B, and the ARTO Working Group members et\u00a0al (2023) Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J\u00a0Clin Oncol 41:5561\u20135568","journal-title":"J Clin Oncol"},{"key":"2520_CR2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","volume":"26","author":"T Niazi","year":"2025","unstructured":"Niazi\u00a0T, Saad\u00a0F, Saad\u00a0F, Tisseverasinghe\u00a0S et\u00a0al (2025) Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 26:1158\u20131167","journal-title":"Lancet Oncol"},{"key":"2520_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost\u00a0P, Reynders\u00a0D, Decaestecker\u00a0K et\u00a0al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J\u00a0Clin Oncol 36:446\u2013453","journal-title":"J Clin Oncol"},{"key":"2520_CR4","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S et\u00a0al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial. J\u00a0Clin Oncol 38:2830\u20132838","journal-title":"J Clin Oncol"},{"key":"2520_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips\u00a0R, Shi\u00a0WY, Deek\u00a0M et\u00a0al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659","journal-title":"JAMA Oncol"},{"key":"2520_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","volume":"88","author":"AD Sherry","year":"2025","unstructured":"Sherry\u00a0AD, Siddiqui\u00a0BA, Haymaker\u00a0C et\u00a0al (2025) Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial. Eur Urol 88:496\u2013509","journal-title":"Eur Urol"},{"key":"2520_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang\u00a0C, Sherry\u00a0AD, Haymaker\u00a0C et\u00a0al (2023) Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol 9:825\u2013834","journal-title":"JAMA Oncol"},{"key":"2520_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","volume":"27","author":"C Tang","year":"2026","unstructured":"Tang\u00a0C, Sherry\u00a0AD, Hwang\u00a0H et\u00a0al (2026) Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X\u2011MET collaboration. Lancet Oncol 27:181\u2013190","journal-title":"Lancet Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02520-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:58:17Z","timestamp":1779890297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2520"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02520-5","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Dunst gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}